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Abstract
Background—Epithelioid trophoblastic tumor (ETT) is a recently described subtype of 
gestational trophoblastic neoplasia (GTN). Its diagnosis requires a high level of suspicion because 
it is often mistaken for more common cervical or uterine corpus epithelial neoplasms.
Case—This is a 39-year-old woman who presented with a cervical mass and positive human 
chorionic gonadotropin and was diagnosed with both locally advanced squamous cell cervical 
carcinoma and nonmetastatic GTN. She was treated unsuccessfully with concurrent intravenous 
cisplatin plus pelvic radiation and single-agent intravenous methotrexate. A retrospective review of 
the cervical biopsy using immunohistochemistry as well as genotyping of the tumor changed the 
original diagnosis to ETT. It is known that ETT is relatively unresponsive to chemotherapy 
compared with most other types of GTN; therefore, surgery would have been the optimal 
treatment. She died despite multiple salvage chemotherapies.
Conclusions—Malignant GTN is one of the most curable gynecologic malignancies; however, 
its correct diagnosis is critical for the appropriate treatment. It can be easily misdiagnosed as a 
carcinoma because of their morphologic similarity. Genetic finger-printing and 
immunohistochemistry are potentially valuable tools to confirm the diagnosis of ETT.
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Malignant gestational trophoblastic neoplasia (GTN) is one of the most curable gynecologic 
malignancies; however, its correct diagnosis is critical for the appropriate treatment. 
Gestational trophoblastic neoplasia is a type of gestational trophoblastic disease that consists 
of persistent or invasive disease. Gestational trophoblastic neoplasia is divided into 4 tumor 
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subtypes including invasive mole, choriocarcinoma, placental-site trophoblastic tumor, and 
epithelioid trophoblastic tumor (ETT).
Epithelioid trophoblastic tumor was first described recently by Shih et al1 in 1998 as a 
separate entity, and since then, only 70 cases have been reported. Most cases occur in 
reproductive-age women after a term pregnancy; however, cases have also been reported in 
postmenopausal women and one third occur after molar pregnancies or spontaneous 
abortions. Two thirds of patients present with local, nonmetastatic disease and is curable in 
approximately 90% if treated appropriately.2 The correct diagnosis of ETT, however, 
requires a high level of suspicion and potentially the use of DNA genotyping and 
immunohistochemistry (IHC).
The diagnosis of ETT is challenging because of its morphologic similarity to carcinoma. 
Macroscopically, ETT appears as a solid-to-cystic well-defined mass that is usually confined 
to the lower uterine segment or cervix. Microscopically, ETT consists of a neoplastic 
proliferation of intermediate trophoblasts with eosinophilic cytoplasm resembling keratin 
and often replacing the endocervical epithelium. The differentiation between ETT and 
squamous cell carcinoma (SCC) of the cervix is therefore challenging.3
The correct diagnosis is critical because the treatment of ETT is quite different from the 
treatment of most other types of GTN or cervical cancer. Epithelioid trophoblastic tumor is 
relatively resistant to both chemotherapy and radiotherapy compared with the more common 
subtypes of GTN such as the highly chemosensitive invasive mole or choriocarcinoma. 
Similar to placental-site trophoblastic tumor, the treatment of ETT is primarily surgery.4,5
CASE
This is a case report of a 39-year-old gravida 6 para 5 Hispanic woman who initially 
presented in October 2006 to a community emergency department with a 2-month history of 
urinary retention and suprapubic pain that immediately became worse. She was then referred 
to our institution. Although she reported having a bilateral tubal ligation 7 years previously, 
she had a spontaneous abortion 18 months before her current presentation. This abnormal 
pregnancy was managed expectantly. She had 5 prior normal vaginal deliveries. She denied 
any history of abnormal Papanicolaou tests, and her last Papanicolaou test was 1 year before 
presentation. On further questioning, she reported postcoital bleeding since the time of her 
spontaneous abortion.
On examination, she was found to have a 10-cm exophytic and necrotic cervical mass 
compressing the bladder and the urethra. There was no pelvic sidewall involvement. She had 
a human chorionic gonadotropin (hCG) level of 965 mIU/mL and a hemoglobin level of 8.8 
g/dL. A computed tomographic (CT) scan of her pelvis revealed a 10-cm pelvic mass and 
bilateral hydronephrosis without evidence of local tissue infiltration or retroperitoneal 
lymphadenopathy. A CT scan of her head, chest, and abdomen did not reveal a metastatic 
disease. Her pelvic ultrasound showed a 10-cm cervical mass but did not reveal an 
intrauterine pregnancy. A biopsy of her cervical mass was consistent with a moderately to 
poorly differentiated SCC.
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She was therefore diagnosed with 2 primary malignancies: SCC of the cervix FIGO stage 
IIIB due to hydronephrosis and nonmetastatic GTN based purely on persistent elevated hCG 
because there was no tissue diagnosis of GTN at that time.
She was treated concurrently for both primary malignancies. She was treated with whole 
pelvic radiation of 45 Gy and 6 doses of radiosensitizing intravenous (IV) cis-platin 40 
mg/m2 weekly that was completed in December 2006 followed by a high-dose rate 
brachytherapy (85 Gy total to point A) that was completed in February 2007. Her GTN was 
treated with IV methotrexate 30 mg/m2 weekly. At the completion of this treatment, she was 
believed to have a partial response of her cervical carcinoma with a decrease in size of the 
cervical mass from 10 to 4 cm on the second CT scan. There was a complete response of her 
GTN with a decrease in hCG level from 965 to 5 mIU/mL. Soon after treatment, however, 
her hCG level began to rise again, and actinomycin D 1.2 mg/m2 IV was started every 2 
weeks.
When her hCG level continued to rise despite single-agent actinomycin D, the original 
diagnosis of 2 primary malignancies was questioned, and her case was presented to the 
multidisciplinary tumor board. As recommended, a second biopsy of the cervical mass was 
performed and was consistent with ETT. A positron emission tomographic/CT scan revealed 
pelvic lymphadenopathy. A percutaneous biopsy of the enlarged iliac node was also 
consistent with ETT.
She was started on etoposide, methotrexate, actinomycin D, cyclophosphamide, and 
vincristine, but because of the continued elevation of her hCG level, her chemotherapy was 
changed to etoposide, methotrexate, actinomycin D, and cisplatinum in March 2007. She 
received 2 cycles of etoposide, methotrexate, actinomycin D, and cisplatinum. A second 
positron emission tomography/CT scan in November indicated disease progression with a 
new left periaortic lymph node metastasis and enlarged bilateral iliac lymph nodes in 
addition to the cervical mass. She was started on paclitaxel, ifosfamide, and cisplatin of 
which she received 4 cycles. Further progression of the left periaortic and bilateral internal 
iliac lymph nodes was noted. The decision to initiate chemotherapy with paclitaxel, 
ifosfamide, and bevacizumab was made. After cycle 3, bevacizumab was discontinued 
because of hemorrhagic cystitis. She had 1 more cycle of dose-reduced ifosfamide with 
mesna and paclitaxel. Her hCG level was never less than 400 mIU/mL. Because of a strong 
desire to continue aggressive therapy, palliative oral capecitabine was given. Her disease 
progressed (Fig. 1), and she died of disease 2 years after her initial presentation.
As part of this case report, a retrospective molecular analysis was performed using IHC and 
genetic fingerprinting. Figure 2 depicts an hematoxylin and eosin stain of the malignant 
tissue. Figure 3 illustrates the IHC findings, and Table 1 shows the results of genetic 
fingerprinting. The hypothesis was that these techniques could have been applied to her 
initial cervical biopsy slides to confirm a diagnosis of GTN and exclude the diagnosis of 
SCC. In Figure 3, dark brown pigmentation (A–C) signifies expression of the proteins in 
question, whereas light blue (D–F) indicates no expression of the protein. As anticipated, 
hCG, inhibin, and cytokeratin 18 were all positive. The antibody to cytokeratin 5/6, usually 
positive in SCC, was absent. Human placental lactogen, usually positive in placental-site 
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trophoblastic tumor, was also absent. The P57 gene is a paternally imprinted and maternally 
expressed protein. It was negative, suggesting that her spontaneous abortion after her 
bilateral tubal ligation was, in fact, a complete hydatidiform mole that led to the 
development of ETT. Figure 3G illustrates p57 staining of intermediate trophoblasts, a 
positive control.
To further confirm that this patient’s initial cervical biopsy was GTN rather than SCC, 
genetic fingerprinting was performed. The tumor and adjacent nontumor tissues were 
genetically compared. It is expected that tumor derived from host tissue has the same genetic 
fingerprint as the host tissue.6 Our results (Table 1) show mismatched alleles in the tumor 
compared with host tissue in 3 of 6 markers, suggesting the tumor to contain both maternal 
and paternal DNA due to a complete molar pregnancy. The maternal allele is identified in 5 
of 6 markers but is absent from D21S11, suggesting the presence of a mutation in the 
tumor.7 This is a known pitfall when tumor samples are used for identity testing.8
COMMENT
Epithelioid trophoblastic tumor presents a very rare form of trophoblastic disease that is 
commonly misdiagnosed. Seventy cases have been reported in the literature.1 Clinically, 
ETT primarily occurs in reproductive-age women up to 18 years after a prior gestation. Most 
ETTs occur after a full-term pregnancy, but approximately one third arise after a 
spontaneous abortion or hydatidiform mole.2 Vaginal bleeding is the presenting symptom in 
two thirds of patients; approximately one third of patients present with metastatic disease.2 
Serum hCG levels are elevated, but usually do not exceed 2500 mIU/mL. Prognosis is 
similar to placental site trophoblastic tumor (PSTT), another rare form of gestational 
trophoblastic neoplasia, but a minority of ETTs act more malignant and present a challenge 
in terms of treatment. When ETT results in mortality, the cause is most commonly 
widespread metastatic disease.
Histologically, the growth of ETT is nodular, with monomorphic cell nests that display an 
eosinophilic to clear cytoplasm within a hyaline matrix. Epithelioid trophoblastic tumors are 
composed of chorionic-type intermediate trophoblasts based on histologic characteristics 
and molecular markers.9 Necrosis, apoptotic cells, and numerous mitoses are characteristic 
features of ETT, reflecting its rapid growth and clinical aggressiveness. Epithelioid 
trophoblastic tumor can easily be mistaken for other tumors. It is most often confused with 
SCC because of its frequent involvement of the lower uterine segment or endocervix and 
because of its epithelioid histologic appearance. It can also be erroneously diagnosed as 
adenocarcinoma because of the presence of rosettes and glandlike structures on microscopic 
evaluation.
This case illustrates 2 important diagnostic concepts in terms of gynecologic malignancies. 
First, any prior abortion that was managed expectantly without ultrasonic or pathologic 
diagnosis should heighten concern for possible abnormal pregnancy such as a molar 
pregnancy as in this case. Second, an elevated β-hCG level in a nonpregnant woman should 
always prompt further workup for GTN. Two primary rare cancers would be unusual, and 
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again this diagnosis should likely be challenged. Nonetheless, ETT is rare and easily 
misdiagnosed, and treatment is often challenging.
Immunohistochemistry and genetic fingerprinting are 2 potential modalities to differentiate 
between ETT and other tumor subtypes. Epithelioid trophoblastic tumor normally shows 
expression of hCG, inhibin, and cytokeratin 18. Antibodies to cytokeratin 5/6 and human 
placental lactogen are usually not expressed in ETT but are expressed in SCC and placental-
site trophoblastic tumor, respectively. Genetic fingerprinting is used to compare tumor tissue 
with host tissue. Tumor tissue with a different DNA can be explained by tumor caused by 
foreign DNA as is the case in ETT caused by a complete molar pregnancy. Of note, IHC and 
genetic fingerprinting would likely only be performed and useful in cases where ETT was 
already suspected, in which case the diagnosis could possibly be made by an astute 
pathologist without further staining or genetic studies.
In this case, a correct diagnosis of epithelial trophoblastic tumor would have significantly 
affected the therapeutic decisions and, possibly, outcome. For example, radiation may not 
have been the treatment of choice had this patient been correctly diagnosed. Although the 
tumor mass did decrease in size after radiation treatment, it is believed that her radiation 
limited the ability for cytotoxic drugs to be delivered to the tumor bed. Even so, it is known 
that epithelial trophoblastic tumors are not as sensitive to chemotherapy as other types of 
gestational trophoblastic tumors; therefore, surgery would have been the optimal choice of 
treatment had the correct diagnosis been made. Diagnosis of ETT requires a high index of 
suspicion and sophisticated pathologic testing. Immunohistochemistry and DNA genotyping 
can be used in rare cases such as this one to differentiate between SCC of the cervix and 
malignant GTN.
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Positron emission tomographic/CT scan revealing widely metastatic disease (red arrows). 
Note physiologic isotope uptake in brain, renal collecting systems, and bladder.
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Hematoxylin and eosin stain of the malignant tissue.
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Immunohistochemistry stains. A to C, Dark brown indicating a positive expression of the 
protein in question. D to F, Light blue indicates a negative result with no expression of the 
protein of interest. β-hCG (A), inhibin (B), and cytokeratin 18 (C). These stains support a 
diagnosis of ETT. D, IHC stain for cytokeratin 5/6. This excludes a diagnosis of SCC. E, 
IHC stain for human placental lactogen. This argues against a diagnosis of placental-site 
trophoblastic tumor. F, IHC p57 stain of ETT. This is negative and confirms a prior complete 
molar gestation. G, IHC p57 stain of intermediate trophoblasts—positive control.
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TABLE 1




D3S1358 15, 17 15, 17 Match
vWA 16, 19 16, 18 Mismatch
D5S818 11, 13 11, 13* Mismatch
D13S317 12, 14 10, 12 Mismatch
D8S1179 10, 15 10, 15 Match
D21S11 29.2, 32 28, 30 Mismatch
The polymerase chain reaction amplification system used for DNA genotyping was the AmpFISTR Profiler Plus ID PCR amplification kit (Applied 
Biosystems).
*
Gestational trophoblastic neoplasia (11, 13) alleles displayed instability.
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